NCT00841373

Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Southern New England Retina Associates · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The object of the study is to compare treatment of iris/angle neovascularization with panretinal photocoagulation (laser) to treatment with panretinal photocoagulation and an anti-angiogenic drug: ranibizumab.

Detailed description

A.To obtain preliminary data on the safety and tolerability of ranibizumab (0.5 mg)in patients with new or progressive neovascularization of the iris or angle due to retinal ischemic diseases in addition to treatment with PRP using the incidence and severity of adverse events identified by subjenc reporting vital signs, and ocular examition. B.To assess the proportion of patients who fail to experience regression of iris and angle neovascularization documented by the clinical examination, iris florescein angiography and gonioscopic evaluation.

Conditions

• Retinal Ischemia

Interventions

Type	Name	Description
PROCEDURE	Panretinal Photocoagulation	Panretinal Photocoagulation treatment
PROCEDURE	Panretinal Photocoagulation and intravitreal injection of ranibizumab	Panretinal photocoagulation and ranibizumab

Timeline

• Start date: 2007-07-01
• Primary completion: 2009-01-01
• Completion: 2010-01-01
• First posted: 2009-02-11
• Last updated: 2014-11-19

Locations

1 site across 1 country: United States